2019

Professional development Vacancies
2019
loperamide

Dear applicants! The Pharmacovigilance Risk Assessment Committee (PRAC), based on the evaluation of the analysis of Periodic Safety Update Reports (PSURs), relying…

Read more
nitrous oxide

Dear applicants, the Pharmacovigilance Risk Assessment Committee (PRAC), based on the assessment of the analysis of Periodic Safety Update Reports (PSURs) for…

Read more
oxycodone

Dear applicants! The Pharmacovigilance Risk Assessment Committee (PRAC), based on the evaluation of the analysis of Periodic Safety Update Reports (PSURs) for…

Read more
Ombitasvir, paritaprevir, ritonavir

Dear applicants! The Pharmacovigilance Risk Assessment Committee (PRAC), based on the assessment of the analysis of Periodic Safety Update Reports (PSURs) for…

Read more
Nalmefene

Dear applicants! The Pharmacovigilance Risk Assessment Committee (PRAC), based on the evaluation of the analysis of Periodic Safety Update Reports (PSURs) for…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing Gabapentin

Dear applicants! The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (PRAC EMA), having considered all available evidence from the literature, clinical…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing Biotin

Dear applicants! The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (PRAC EMA), having reviewed all available evidence from the literature, EudraVigilance,…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing Carbimazole, Thiamazole

Dear applicants! The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (PRAC EMA), based on an analysis of available sources (EudraVigilance, literature),…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing Perindopril

Dear applicants! The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (PRAC EMA), having considered the available evidence on Raynaud’s syndrome, and…

Read more
Regarding amendments to the instruction for medical use of medicinal products containing Dulaglutide, Exenatide, Liraglutide

Dear applicants! The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (PRAC EMA) has reviewed the available data on spontaneous cases of…

Read more